Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Lisa Haley

Concomitant Monitoring ofWT1andFLT3-ITDexpression inFLT3-ITDacute Myeloid Leukemia Patients: Which Should We Trust as a Minimal Residual Disease Marker?

American Journal of Hematology

Hematology

2017

English

Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences With Adult Counterparts and Other Pediatric Gliomas

English

Related publications

Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia

English

Plasma-Derived Exosomes in Acute Myeloid Leukemia for Detection of Minimal Residual Disease: Are We Ready?

Expert Review of Molecular Diagnostics

English

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?

Journal of Clinical Medicine

2017

English

Monitoring of Minimal Residual Disease in Adult Acute Myeloid Leukemia Using Peripheral Blood as an Alternative Source to Bone Marrow

Haematologica

Hematology

2007

English

Estimation of Molecular Upper Remission Limit for Monitoring Minimal Residual Disease in Peripheral Blood of Acute Myeloid Leukemia Patients by WT1 Expression

Experimental and Therapeutic Medicine

English

FLT3 as a Marker of Minimal Residual Disease: Time to Re-Think?

American Journal of Hematology

Hematology

2017

English

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Mediterranean Journal of Hematology and Infectious Diseases

Infectious Diseases

Hematology

2016

English

Serological Normalisation as a Surrogate Marker for Minimal Residual Disease Negativity in Multiple Myeloma

British Journal of Haematology

Hematology

2018

English

Quantitative Assessment of Minimal Residual Disease in Acute Myeloid Leukemia Carrying Nucleophosmin (NPM1) Gene Mutations

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Lisa Haley

Concomitant Monitoring ofWT1andFLT3-ITDexpression inFLT3-ITDacute Myeloid Leukemia Patients: Which Should We Trust as a Minimal Residual Disease Marker?

Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences With Adult Counterparts and Other Pediatric Gliomas

Related publications

Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia

Plasma-Derived Exosomes in Acute Myeloid Leukemia for Detection of Minimal Residual Disease: Are We Ready?

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?

Monitoring of Minimal Residual Disease in Adult Acute Myeloid Leukemia Using Peripheral Blood as an Alternative Source to Bone Marrow

Estimation of Molecular Upper Remission Limit for Monitoring Minimal Residual Disease in Peripheral Blood of Acute Myeloid Leukemia Patients by WT1 Expression

FLT3 as a Marker of Minimal Residual Disease: Time to Re-Think?

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Serological Normalisation as a Surrogate Marker for Minimal Residual Disease Negativity in Multiple Myeloma

Quantitative Assessment of Minimal Residual Disease in Acute Myeloid Leukemia Carrying Nucleophosmin (NPM1) Gene Mutations